リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Trend of Diabetes Care for Elderly Patients at a Single Center from 2009 to 2019」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Trend of Diabetes Care for Elderly Patients at a Single Center from 2009 to 2019

Furukawa, Yasuyuki Nishizawa, Morito Nakano, Hirofumi Yui, Hiroshi 信州大学 DOI:10.11441/shinshumedj.71.149

2023.06.13

概要

Objective : We performed a narrative analysis of the data of diabetes of elderly patients how the Japanese Clinical Practice Guidelines have worked on glycemic control. Methods : We analyzed two sets of data, one from patients who visited initially during April and June in 2009, 2014 and 2019, respectively, and the other from 168 patients followed for 10 years successively, with analysis on Hb (hemoglobin) A1c and the number of hypoglycemic agents (prescriptions)/patient. Results : In the first set, the patient numbers were 351, 487 and 572 in each year with a mean age of 68.5, 70.5 and 71.7 years, respectively. The mean HbA1c, 7.3～7.4 ％, was not significantly different from each year, but prescriptions/patient were greater in 2019 than in 2009, 1.7±1.3 (mean±SD) vs 1.2±1.1. Upon division into Groups 1 to 3 by age, ＜65 years, 65 to 74 years, and ≥ 75 years old, respectively, HbA1c was greater in Group 1 than in Groups 2 and 3, and so were prescriptions/patient, especially DPP-4i and SGLT-2i. In the second set, the mean HbA1c was greater with time and so were prescriptions/patient, 1.2±1.1 in 2009 vs 2.1±1.4 in 2019. Upon division into three groups (T1, T2 and T3) by age tertile, with a mean age of 55.7, 66.0, and 75.4 years in 2009, respectively, HbA1c was higher and the fraction of the patients having ＜7.0 ％ HbA1c less in T1 than in T3. Prescriptions/patient were greater in T1 than in T3 all through the observation period. Conclusion : Diabetes control has been at a reasonable level in the elderly patients ( ≥ 65 years) but not in the middle-aged.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1） Haneda M, Noda M, Origasa H, et al : Japanese clinical practice guideline for diabetes 2016. J Diabetes Investig

9 : 657-697, 2018 [Erratum, J Diabetes Investig 10 : 190, 2019]

2）

Davies MJ, D’Alessio DA, Fadkin J, et al : Management of hyperglycemia in type 2 diabetes, 2018. A consensus

report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes

(EASD). Diabetes Care 41 : 2669-2701, 2018

3）

Hermansen K, Kipnes M, Luo E, et al : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in

patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Diabetes Obes Metab 9 : 733-745, 2007

4） Kadowaki T, Tajima N, Odawara M, et al : Addition of sitagliptin to ongoing metformin monotherapy improves

glycemic control in Japanese patients with type 2 diabetes over 52 weeks. J Diabetes Invest 18 : 174-181, 2013

5）

Monami M, Nardini C, Mannucci E : Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2

diabetes : a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16 : 457-466, 2014

6）

Zinman B, Wanner C, Lachin JM, et al : EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular

outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015

7）

UK prospective diabetes study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin

compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).

Lancet 352 : 837-853, 1998 [Erratum, Lancet 354 : 602, 1999]

8） UK Prospective Diabetes Study (UKPDS) Group : Effect of intensive blood-glucose control with metformin on

complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 : 854-865, 1998 [Erratum, Lancet

352 : 1558, 1998]

9） Duckworth W, Abraira C, Moritz T, et al for the VADT investigators : Glucose control and vascular complications in

veterans with type 2 diabetes. N Engl J Med 360 : 129-139, 2000

10） The ADVANCE Collaborative Group : Intensive blood glucose control and vascular outcomes in patients with type 2

diabetes. N Engl J Med 358 : 2560-2572, 2008

11） The ACCORD Study Group : Effects of intensive blood glucose lowering in type 2 diabetes. N Engl J Med 358 :

2545-2559, 2008

12） Kuusisto J, Mykkanen L, Pyorala K, Laakso M : NIDDM and its metabolic control predict coronary heart disease in

elderly subjects. Diabetes 43 : 960-967, 1994

13）

Cukierman T, Gerstein HC, Willamson JD : Cognitive decline and dementia in diabetes--systematic overview of

prospective observational studies. Diabetologia 48 : 2460-2469, 2005

14） Rawshani A, Rawshani A, Franzen S, et al : Risk factors, mortality, and cardiovascular outcomes in patients with

type 2 diabetes. N Engl J Med 379 : 633-644, 2018

15）

Coppola A, Sasso L, Banasco A, Giustina A, Cazzaruso C : The role of patient education in the prevention and

management of type 2 diabetes : an overview. Endocrine 53 : 18-27, 2016

16） Mendenhall E, Kohrt BA, Norris SA, Ndetei D, Prabhakaran D : Non-communicable syndemics : poverty, depression,

and diabetes among low-income populations. Lancet 389 : 951-963, 2017

17） American Diabetes Association : Standards of medical care in Diabetes-2020. Diabetes Care 43 : S4-S212, 2020

（2022. 12. 13 received ; 2023. 1. 23 accepted） 158

Shinshu Med J Vol. 71

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る